US Pharma MarketingNura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration
Nura Bio raises $73.8M Series B to advance oral SARM1 inhibitors NB-4746 in ALS and NB-9402 through early clinical trials. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
The neurodegenerative disease-focused company Nura Bio said Monday it has secured $73.8 million in a Series B raise to fund two programs through early clinical trials.
The cash should support Nura’s clinical work over the ...
Source: Endpoints News